{"id":"W2282455907","doi":"10.1177/2048872616633880","title":"Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial","year":2016,"lang":"en","type":"article","venue":"European Heart Journal Acute Cardiovascular Care","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Janssen Research and Development; Servier; Regado Biosciences; Medicines Company; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Stanford Bio-X; MyoKardia; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Sanofi; American Heart Association","keywords":"Thienopyridine; Medicine; Acute coronary syndrome; Cardiology; Internal medicine; Myocardial infarction; Clinical endpoint; Stroke (engine); Clopidogrel; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008609337,0.0002162517,0.0006738329,0.000169655,0.0001989045,0.00006663876,0.00009982096,0.00006828278,0.00001216899],"category_scores_gemma":[0.0002066806,0.0001109852,0.0003100033,0.0003240977,0.0001198353,0.0003587838,0.00009897279,0.0003190021,0.000004685816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002200764,"about_ca_system_score_gemma":0.0001314651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004102038,"about_ca_topic_score_gemma":0.000002282206,"domain_scores_codex":[0.9967771,0.000790099,0.0004993562,0.0003445074,0.001362796,0.000226153],"domain_scores_gemma":[0.9976837,0.0003758915,0.0002771655,0.0004586368,0.0009707821,0.0002338468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3084303,0.0007313987,0.269151,0.000348163,0.1207887,0.004259931,0.02330435,0.001778876,0.1302704,0.00002822966,0.01576211,0.1251466],"study_design_scores_gemma":[0.03596856,0.004165372,0.9287609,0.00055327,0.003508563,0.001560131,0.0005211989,0.00001342522,0.002811256,0.00000132088,0.02192522,0.0002107152],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910195,0.001046418,0.003572194,0.002351,0.000121697,0.001664841,0.0001599313,0.00001707692,0.0000472712],"genre_scores_gemma":[0.9955332,0.001932779,0.00167225,0.000359721,0.0002707258,0.0000111961,0.0000535001,0.00005735031,0.0001093314],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.65961,"threshold_uncertainty_score":0.4525844,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02589130734681251,"score_gpt":0.2723322871805499,"score_spread":0.2464409798337374,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}